French healthcare company Sanofi announced on Friday a share buyback plan worth up to 2 billion euros ($2.1 billion), which would be done between now and the end of December.

The US Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for brensocatib for patients with ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

Kura Oncology and Japan’s Kyowa Kirin have announced that their menin inhibitor ziftomenib met the primary endpoint in a ...